1. |
Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev, 2013, 24(4): 373-384.
|
2. |
Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem, 2013, 59(11): 1550-1552.
|
3. |
Aw Yong KM, Zeng Y, Vindivich D, et al. Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis. J Cell Physiol, 2014, 229(3): 362-373.
|
4. |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386.
|
5. |
国家消化系统疾病临床医学研究中心, 中华医学会消化内镜学分会, 中国医师协会消化医师分会. 中国巴雷特食管及其早期腺癌筛查与诊治共识(2017, 万宁). 中华内科杂志, 2017, 56(9): 701-711.
|
6. |
Duggan SP, Behan FM, Kirca M, et al. An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett’s oesophagus, which regulates NF-kappaB activation and cytokine levels. Carcinogenesis, 2010, 31(5): 936-945.
|
7. |
Fisher OM, Levert-Mignon AJ, Lord SJ, et al. MIC-1/GDF15 in Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Cancer, 2015, 112(8): 1384-1391.
|
8. |
Wang XB, Jiang XR, Yu XY, et al. Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci, 2014, 105(2): 176-185.
|
9. |
Skipworth RJ, Deans DA, Tan BH, et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer, 2010, 102(4): 665-672.
|
10. |
国家消化系统疾病临床医学研究中心, 中华医学会内镜学分会(CSDE, Chinese Society of Digestive Endoscopy), 中华医学会健康管理学分会, 等. 中国早期胃癌筛查流程专家共识意见(草案)(2017 年, 上海). 中华健康管理学杂志, 2018, 12(1): 8-14.
|
11. |
Colucci R, Antonioli L, Bernardini N, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. J Pharmacol Exp Ther, 2012, 342(1): 140-149.
|
12. |
Li YL, Cui W, Gao F, et al. Downregulation of growth differentiation factor-15 in trichostatin A-induced apoptosis could play a role in progression of gastric cancer. Int J Clin Exp Pathol, 2015, 8(7): 8136-8142.
|
13. |
Han M, Dai D, Yousafzai NA, et al. CXXC4 activates apoptosis through up-regulating GDF15 in gastric cancer. Oncotarget, 2017, 8(61): 103557-103567.
|
14. |
Lu L, Ma GQ, Liu XD, et al. Correlation between GDF15, MMP7 and gastric cancer and its prognosis. Eur Rev Med Pharmacol Sci, 2017, 21(3): 535-541.
|
15. |
Blanco-Calvo M, Tarrío N, Reboredo M, et al. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. Future Oncol, 2014, 10(7): 1187-1202.
|
16. |
国家卫生计生委医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017 年版). 中华胃肠外科杂志, 2018, 21(1): 92-106.
|
17. |
Choi HJ, Do KH, Park JH, et al. Early epithelial restitution by nonsteroidal anti-inflammatory drug-activated gene 1 counteracts intestinal ulcerative injuries. J Immunol, 2016, 197(4): 1415-1424.
|
18. |
Baek SJ, Okazaki R, Lee SH, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology, 2006, 131(5): 1553-1560.
|
19. |
Brown DA, Hance KW, Rogers CJ, et al. Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidemiol Biomarkers Prev, 2012, 21(2): 337-346.
|
20. |
Lee J, Fricke F, Warnken U, et al. Reconstitution of TGFBR2-mediated signaling causes upregulation of GDF-15 in HCT116 colorectal cancer cells. PLoS One, 2015, 10(6): e0131506.
|
21. |
Li C, Wang J, Kong J, et al. GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget, 2016, 7(1): 860-872.
|
22. |
Danta M, Barber DA, Zhang HP, et al. Macrophage inhibitory cytokine-1/growth differentiation factor-15 as a predictor of colonic neoplasia. Aliment Pharmacol Ther, 2017, 46(3): 347-354.
|
23. |
Chen H, Qian J, Werner S, et al. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol, 2017, 9: 517-526.
|
24. |
Li C, Wang X, Casal I, et al. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med, 2016, 20(8): 1420-1426.
|
25. |
Wang J, Li W, Wang Y, et al. The H6D genetic variation of GDF15 is associated with genesis, progress and prognosis in colorectal cancer. Pathol Res Pract, 2015, 211(11): 845-850.
|
26. |
Mehta RS, Chong DQ, Song M, et al. Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality. Gastroenterology, 2015, 149(3): 614-622.
|
27. |
Mehta RS, Song M, Bezawada N, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst, 2014, 106(4): dju016.
|
28. |
Wang X, Yang Z, Tian H, et al. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget, 2017, 8(15): 24892-24901.
|
29. |
中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017 年版). 中华消化外科杂志, 2017, 16(7): 705-720.
|
30. |
Hsiao EC, Koniaris LG, Zimmers-Koniaris T, et al. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol, 2000, 20(10): 3742-3751.
|
31. |
Si Y, Liu X, Cheng M, et al. Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PLoS One, 2011, 6(5): e19967.
|
32. |
Zimmers TA, Jin X, Gutierrez JC, et al. Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. J Cancer Res Clin Oncol, 2008, 134(7): 753-759.
|
33. |
Chung HK, Kim JT, Kim HW, et al. GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep, 2017, 7(1): 17238.
|
34. |
Koo BK, Um SH, Seo DS, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int, 2018, 38(4): 695-705.
|
35. |
Krawczyk M, Zimmermann S, Hess G, et al. Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease. PLoS One, 2017, 12(3): e0173506.
|
36. |
Lee ES, Kim SH, Kim HJ, et al. Growth differentiation factor 15 predicts chronic liver disease severity. Gut Liver, 2017, 11(2): 276-282.
|
37. |
Liu X, Chi X, Gong Q, et al. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma. PLoS One, 2015, 10(5): e0127518.
|
38. |
中国抗癌协会. 远端胆管癌规范化诊治专家共识(2017). 中华肝胆外科杂志, 2018, 24(1): 1-8.
|
39. |
Subbannayya T, Leal-Rojas P, Barbhuiya MA, et al. Macrophage migration inhibitory factor—a therapeutic target in gallbladder cancer. BMC Cancer, 2015, 15: 843.
|
40. |
Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res, 2004, 10(7): 2386-2392.
|
41. |
Koniaris LG. Induction of MIC-1/growth differentiation factor-15 following bile duct injury. J Gastrointest Surg, 2003, 7(7): 901-905.
|
42. |
Ji H, Lu HW, Li YM, et al. Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15. Mol Med Rep, 2015, 12(3): 3841-3848.
|
43. |
Wang X, Li Y, Tian H, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer, 2014, 14: 578.
|
44. |
Kaur S, Chakraborty S, Baine MJ, et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One, 2013, 8(2): e55171.
|
45. |
Montes AF, Villarroel PG, Ayerbes MV, et al. Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis. J Cancer Res Ther, 2017, 13(2): 240-245.
|
46. |
Mohamed AA, Soliman H, Ismail M, et al. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. Pancreatology, 2015, 15(1): 34-39.
|
47. |
Kaur S, Baine MJ, Guha S, et al. NGAL, MIC-1, and CA19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas. Pancreas, 2013, 42(3): 494-501.
|
48. |
Loosen SH, Neumann UP, Trautwein C, et al. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol, 2017, 39(6): 1010428317692231.
|
49. |
Torres C, Perales S, Alejandre MJ, et al. Serum cytokine profile in patients with pancreatic cancer. Pancreas, 2014, 43(7): 1042-1049.
|